Urokinase plasminogen activator colocalizes with CD25+ cells in atherosclerotic vessels

Journal of Vascular Research

Volumn 35, Issue 5, 1998, Pages 318-324

  Falkenberg, Mårten ^a   Giglio, Daniel ^a   Björnheden, Tom ^b   Nygren, Håkan ^a   Risberg, Bo ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Activation; Atherosclerosis; CD25; Immunohistochemistry; Inflammation; Inter leukin 2 receptor ; Macrophages; Urokinase plasminogen activator

Indexed keywords

CD68 ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; UROKINASE;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; INFLAMMATION; MACROPHAGE ACTIVATION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTERIOSCLEROSIS; CELL MOVEMENT; FIBRINOLYSIS; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; MIDDLE AGED; PLASMINOGEN ACTIVATORS; RECEPTORS, INTERLEUKIN-2; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031728177     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025601     Document Type: Article

References (23)

1. Hansson GK: Immunological control mechanisms in plaque formation. Basic Res Cardiol 1994;89(suppl 1):41-46.
2. Vassalli J, Wohlwend A, Belin D: Urokinase-catalyzed plasminogen acivation at the monocyte/macrophage cell surface: A localized and regulated proteolytic system. Curr Top Microbiol Immunol 1992;181:65-86.
3. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.
4. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-778.
5. van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
6. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds J: The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992;667:1-12.
7. Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor B1 by plasmin. J Cell Biol 1990;110:1361-1367.
8. Fujii S, Hopkins WE, Sobel BE: Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991; 83:645-651.
9. Shireman PK, McCarthy WJ, Pearce WH, Shively VP, Cipollone M, Kwaan HC: Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. J Vasc Surg 1997;25:157-164.
10. Lotti T, Benci M: Plasminogen activators, venous leg ulcers and reepithelialization. Int J Dermatol 1995;34:696-699.
11. Danø K, Andreasen JA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-239.
12. Estreicher A, Muhlhauser J, Carpentier J-L, Orci L, Vassalli J-D: The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-792.
13. Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D: Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81:829-839.
14. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard R: Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation 1997;96:3181-3191.
15. Falkenberg M, Tjärnström J, Örtenwall P, Olausson M, Risberg B: Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels. Thromb Haemost 1996;75:933-988.
16. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckout Y, Shapiro S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-444.
17. Lupu F, Heim D, Bachman F, Hurni M, Kakkar VV, Kruitof EKO: Plasminogen activator expressions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995;1:1444-1455.
18. Schneiderman J, Bordin G, Engelberg I, Adar R, Seiffert D, Thinnes T, Bernstein E, Dilley R, Loskutoff D: Expression of fibrinolytic genes in atherosclerotic aortic aneurysm wall. J Clin Invest 1995;96:639-645.
19. Cox GW, Mathieson BJ, Giardina SL, Varesio L: Characterization of IL-2 receptor expression and function on murine macrophages. J Immunol 1990;145:1719-1726.
20. Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: Regulation of expression and release of the α and β chains (p55 and p75). Res Immunol 1992;143:33-37.
21. Waldman TA: The multi-subunit interleukin-2 receptor. Annu Rev Biochem 1989;58:875-911.
22. Cid MC, Grau JM, Casademont J, Campo E, Coll-Vinent B, Lopez-Soto A, Ingelmo M, Urbano-Marquez A: Immunohistochemical characterization of inflammatory activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. Arthritis Rheum 1994;37:1055-1061.
23. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulazis Z, MacDonald S, Pulford KAF, Stein H, Mason DY: Immunoenzymatic labeling of mononuclear antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-229.